nach oben

Annals of Nuclear Medicine

Erschienen in:

01.10.2014 | Original Article

Comparison of ¹²³I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimer’s disease

verfasst von: Yoshitaka Inui, Hiroshi Toyama, Yuta Manabe, Masayoshi Sarai, Nakao Iwata

Erschienen in: Annals of Nuclear Medicine | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Objective

This study aimed to compare the diagnostic value of ¹²³I-metaiodobenzylguanidine (MIBG) myocardial scintigraphy, N-isopropyl-p[¹²³I]iodoamphetamine (IMP) brain perfusion single-photon emission computed tomography (SPECT), and brain magnetic resonance imaging (MRI) voxel-based morphometry (VBM) for the differentiation of dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD).

Methods

Thirty-five and 34 patients with probable DLB and probable AD, respectively, were enrolled. All patients underwent ¹²³I-MIBG myocardial scintigraphy, ¹²³I-IMP brain perfusion SPECT, and brain MRI. For ¹²³I-MIBG imaging, we calculated early and delayed heart-to-mediastinum (H/M) uptake ratios. Three-dimensional stereotactic surface projections (3D-SSP) were used to analyze the results of ¹²³I-IMP SPECT. VBM with statistical parametric mapping 8 plus diffeomorphic anatomical registration using exponentiated Lie algebra (DARTEL) was used to analyze the brain MRI data.

Results

The area under the receiver operating characteristic curves (AUC) for discriminating DLB and AD was highest (0.882) for the delayed H/M ratio on ¹²³I-MIBG scintigraphy. AUC for z-score measurement in the occipital lobe was 0.818 and that for the extent of gray matter (GM) atrophy in the whole brain was 0.788. AUC for the combination of 3D-SSP and VBM analysis was 0.836. The respective sensitivities and specificities for distinguishing DLB from AD were 97.1 and 100 % for the delayed H/M ratio using ¹²³I-MIBG scintigraphy; 88.6 and 73.5 % for the occipital lobe z-score using 3D-SSP analysis; 85.7 and 64.7 % for the extent of whole brain GM atrophy using voxel-based MRI morphometry; and 91.4 and 76.5 % for the combination of 3D-SSP analysis and VBM.

Conclusions

¹²³I-MIBG myocardial scintigraphy was superior to brain perfusion SPECT and brain MRI using an advanced statistical technique to differentiate DLB and AD.

McKeith I, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, et al; International Psychogeriatric Association Expert Meeting on DLB. Dementia with Lewy bodies. Lancet Neurol. 2004;3:19–28.

McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005;65:1–10.

Watanabe H, Ieda T, Katayama T, Takeda A, Aiba I, Doyu M, et al. Cardiac ¹²³I-meta-iodobenzylguanidine (MIBG) uptake in dementia with Lewy bodies: comparison with Alzheimer’s disease. J Neurol Neurosurg Psychiatry. 2001;70:781–3.PubMedCrossRefPubMedCentral

Yoshita M, Taki J, Yamada M. A clinical role for [¹²³I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer’s-type and dementia with Lewy bodies. J Neurol Neurosurg Psychiatry. 2001;71:583–8.PubMedCrossRefPubMedCentral

Oide T, Tokuda T, Momose M, Oguchi K, Nakamura A, Ohara S, et al. Usefulness of [¹²³I] metaiodobenzylguanidine ([¹²³I]MIBG) myocardial scintigraphy in differentiating between Alzheimer’s disease and dementia with Lewy bodies. Intern Med. 2003;42:686–90.PubMedCrossRef

Orimo S, Amino T, Itoh Y, Takahashi A, Kojo T, Uchihara T, et al. Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease. Acta Neuropathol. 2005;109:583–8.PubMedCrossRef

Inui Y, Toyama H, Manabe Y, Sato T, Sarai M, Kosaka K, et al. Evaluation of probable or possible dementia with Lewy bodies using ¹²³I-IMP brain perfusion SPECT, ¹²³I-MIBG, and ^99mTc-MIBI myocardial SPECT. J Nucl Med. 2007;48:1641–50.PubMedCrossRef

Treglia G, Cason E. Diagnostic performance of myocardial innervation imaging using MIBG scintigraphy in differential diagnosis between dementia with Lewy bodies and other dementias: a systematic review and a meta-analysis. J Neuroimaging. 2012;22:111–7.PubMedCrossRef

McKeith I, O’Brien J, Walker Z, Tatsch K, Booij J, Darcourt J, DLB Study Group, et al. Sensitivity and specificity of dopamine transporter imaging with ¹²³I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–13.PubMedCrossRef

10.

McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s disease. Neurology. 1984;34:939–44.PubMedCrossRef

11.

Solanski KK, Bomanji J, Moyes J, Mather SJ, Trainer PJ, Britton KE. A pharmacological guide to medicines which interfere with the biodistribution of radiolabelled meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 1992;13:513–21.CrossRef

12.

Minoshima S, Berger KL, Lee KS, Mintun MA. An automated method for rotational correction and centering of three-dimensional functional brain images. J Nucl Med. 1992;33:1579–85.PubMed

13.

Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer’s disease using three-dimensional stereotractic surface projections of fluorine-18-FDG PET. J Nucl Med. 1995;36:1238–48.PubMed

14.

Germano G, Erel J, Kiat H, Kavanagh PB, Berman DS. Quantitative LVEF and qualitative regional function from gated thallium-201 perfusion SPECT. J Nucl Med. 1997;38:749–54.PubMed

15.

Mizumura S, Kumita S, Cho K, Ishihara M, Nakajo H, Toba M, et al. Development of quantitative analysis method for stereotactic brain image: assessment of reduced accumulation in extent and severity using anatomical segmentation. Ann Nucl Med. 2003;17:289–95.PubMedCrossRef

16.

Hirata Y, Matsuda H, Nemoto K, Ohnishi T, Hirao K, Yamashita F, et al. Voxel-based morphometry to discriminate early Alzheimer’s disease from controls. Neurosci Lett. 2005;382:269–74.PubMedCrossRef

17.

Matsuda H, Mizumura S, Nemoto K, Yamashita F, Imabayashi E, Sato N, et al. Automatic voxel-based morphometry of structural MRI by SPM8 plus diffeomorphic anatomic registration through exponentiated lie algebra improves the diagnosis of probable Alzheimer disease. Am J Neuroradiol. 2012;33:1109–14.PubMedCrossRef

18.

Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage. 2007;38:95–113.PubMedCrossRef

19.

McKeith IG, Del Ser T, Spano P, Emre M, Wesnes K, Anand R, et al. Efficacy of rivastigmine in dementia with Lewy bodies. A randomized double blind, placebo-controlled intermation study. Lancet. 2000;356:2031–6.PubMedCrossRef

20.

Ikeda M, Mori E, Kosaka K, Iseki E, Hashimoto M, Matsukawa N, et al; Donepezil-DLB Study Investigators. Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study. Dement Geriatr Cogn Disord. 2013;36:229–41.

21.

McKeith I, Fairbairn A, Perry R, Thompson P, Perry E. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. Br J Psychiatry. 1992;305:673–8.

22.

Albin RL, Minoshima S, D’Amato CJ, Frey KA, Kuhl DA, Sima AA. Fluoro-deoxyglucose positron emission tomography in diffuse Lewy body disease. Neurology. 1996;47:462–6.PubMedCrossRef

23.

Ishii K, Yamaji S, Kitagaki H, Immamura T, Hirono N, Mori E. Regional cerebral blood flow difference between dementia with Lewy bodies and AD. Neurology. 1999;53:413–6.PubMedCrossRef

24.

Minoshima S, Foster NL, Sima AA, Frey KA, Albin RL, Kuhl DE. Alzheimer’s disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation. Ann Neurol. 2001;50:358–65.PubMedCrossRef

25.

Lobotesis K, Fenwick JD, Phipps A, Ryman A, Swann A, Ballard C, et al. Occipital hypoperfusion on SPECT in dementia with Lewy bodies but not AD. Neurology. 2001;56:643–9.PubMedCrossRef

26.

Colloby SJ, Fenwick JD, Williams ED, Paling SM, Lobotesis K, Ballard C, et al. A comparison of ^99mTc-HMPAO SPET changes in dementia with Lewy bodies and Alzheimer’s disease using statistical parametric mapping. Eur J Nucl Med Mol Imaging. 2002;29:615–22.PubMedCrossRef

27.

Pasquier J, Michel BF, Brenot-Rossi I, Hassan-Sebbag N, Sauvan R, Gastaut JL. Value of ^99mTc-ECD SPET for the diagnosis of dementia with Lewy bodies. Eur J Nucl Med Mol Imaging. 2002;29:1342–8.PubMedCrossRef

28.

Shimizu S, Hanyu H, Kanetake H, Iwamoto T, Koizumi K, Abe K. Differentiation of dementia with Lewy bodies from Alzheimer’s disease using brain SPECT. Dement Geriatr Cogn Disord. 2005;20:25–30.PubMedCrossRef

29.

Mori T, Ikeda M, Fukuhara R, Nestor PJ, Tanabe H. Correlation of visual hallucinations with occipital rCBF changes by donepezil in DLB. Neurology. 2006;66:935–7.PubMedCrossRef

30.

Hanyu H, Shimizu S, Hirao K, Kanetaka H, Iwamoto T, Chikamori T, et al. Comparative value of brain perfusion SPECT and [123I]MIBG myocardial scintigraphy in distinguishing between dementia with Lewy bodies and Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2006;33:248–53.PubMedCrossRef

31.

Tateno M, Kobayashi S, Shirasaka T, Furukawa Y, Fujii K, Morii H, et al. Comparison of the usefulness of brain perfusion SPECT and MIBG myocardial scintigraphy for the diagnosis of dementia with Lewy bodies. Dement Geriatr Cogn Disord. 2008;26:453–7.PubMedCrossRef

32.

Kantarci K, Ferman TJ, Boeve BF, Weigand SD, Przybelski S, Vemuri P, et al. Focal atrophy on MRI and neuropathologic classification of dementia with Lewy bodies. Neurology. 2012;79:553–60.PubMedCrossRefPubMedCentral

33.

Hashimoto M, Kitagaki H, Imamura T, Hirono N, Shimomura T, Kazui H, et al. Medial temporal and whole-brain atrophy in dementia with Lewy bodies. A volumetric MRI study. Neurology. 1998;51:357–62.PubMedCrossRef

34.

Barber R, Ballard C, McKeith IG, Gholkar A, O’Brien JT. MRI volumetric study of dementia with Lewy bodies: a comparison with AD and vascular dementia. Neurology. 2000;54:1304–9.PubMedCrossRef

35.

O’Brien JT, Paling S, Barber R, Williams ED, Ballard C, McKeith IG, et al. Progressive brain atrophy on serial MRI in dementia with Lewy bodies, AD, and vascular dementia. Neurology. 2001;56:1386–8.PubMedCrossRef

36.

Barber R, Gholkar A, Scheltens P, Ballard C, McKeith IG, O’Brien JT. Medial temporal lobe atrophy on MRI in dementia with Lewy bodies. Neurology. 1999;52:1153–8.PubMedCrossRef

37.

Takahashi R, Ishii K, Miyamoto N, Yoshikawa T, Shimada K, Ohkawa S, et al. Measurement of gray and white matter atrophy in dementia with Lewy bodies using diffeomorphic anatomical registration through exponentiated lie algebra: a comparison with conventional voxel-based morphometry. Am J Neuroradiol. 2010;31:1873–8.PubMedCrossRef

38.

Iwanaga K, Wakabayashi K, Yoshimoto M, Tomita I, Satoh H, Takashima H, et al. Lewy body-type degeneration in cardiac plexus in Parkinson’s and incidental Lewy body diseases. Neurology. 1999;52:1269–71.PubMedCrossRef

39.

Miyamoto T, Miyamoto M, Suzuki K, Nishibayashi M, Iwanami M, Hirata K. ¹²³I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep. 2008;31:717–23.PubMedPubMedCentral

40.

Boeve BF, Silber MH, Fermen TJ, Lin SC, Benarroch EE, Schmeichel AM, et al. Clinicopathologic correlations in 172 cases of rapid eye movement sleep behavior disorder with or without a coexisting neurologic disorder. Sleep Med. 2013;14:754–62.PubMedCrossRefPubMedCentral

41.

Colloby SJ, Firbank MJ, Pakrasi S, Lloyd JJ, Driver I, McKeith IG, et al. A comparison of ^99mTc-exametazime and ¹²³I-FP-CIT SPECT imaging in the differential diagnosis of Alzheimer’s disease and dementia with Lewy bodies. Int Psychogeriatr. 2008;20:1124–40.PubMedCrossRef

42.

Iranzo A, Valldeoriola F, Lomeña F, Molinuevo JL, Serradell M, Salamero M, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behavior disorder: a prospective study. Lancet Neurol. 2011;10:797–805.PubMedCrossRef

43.

Walker Z, Jaros E, Walker RW, Lee L, Livingston G, Ince PG, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007;78:1176–81.PubMedCrossRefPubMedCentral

44.

Treglia G, Cason E, Cortelli P, Gabellini A, Liguori R, Bagnato A, et al. Iodine-123 metaiodobenzylguanidine scintigraphy and iodine-123 ioflupane single photon emission computed tomography in Lewy body diseases: complementary or alternative techniques? J Neuroimaging. 2014;24:149–54.PubMedCrossRef

Titel: Comparison of 123I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimer’s disease
verfasst von: Yoshitaka Inui
Hiroshi Toyama
Yuta Manabe
Masayoshi Sarai
Nakao Iwata
Publikationsdatum: 01.10.2014
Verlag: Springer Japan
Erschienen in: Annals of Nuclear Medicine / Ausgabe 8/2014
Print ISSN: 0914-7187
Elektronische ISSN: 1864-6433
DOI: https://doi.org/10.1007/s12149-014-0873-2

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Comparison of ¹²³I-MIBG myocardial scintigraphy, brain perfusion SPECT, and voxel-based MRI morphometry for distinguishing between dementia with Lewy bodies and Alzheimer’s disease

Abstract

Objective

Methods

Results

Conclusions

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Objective

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Analytical functions for beta and gamma absorbed fractions of iodine-131 in spherical and ellipsoidal volumes

Benefit of cardiac N-13 PET CFR for combined anatomical and functional diagnosis of ischemic coronary artery disease: a pilot study

The prognostic value of mid- and post-treatment [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) in indolent follicular lymphoma

Validation of a short-scan-time imaging protocol for thallium-201 myocardial SPECT with a multifocal collimator

Performance of 18F-FDG PET/CT as a postoperative surveillance imaging modality for asymptomatic advanced gastric cancer patients

Dual-phase 99mTc-MIBI scintigraphy with delayed neck and thorax SPECT/CT and bone scintigraphy in patients with primary hyperparathyroidism: correlation with clinical or pathological variables